Health Care ETFs Take Over Market Leadership Role
The market this year has been characterized by leadership in defensive sectors such as utilities that have been boosted by falling interest rates and conservatism in the late stages of this bull market. While the momentum in utilities has continued to prosper, a new sector has taken over the top leadership spot in this year’s sector rankings.
Health Care SPDR (ETF)
The Health Care SPDR (ETF) (NYSE: XLV) experienced a drop along with the majority of the market in October. However, this ETF has shown tremendous relative strength since then and has pushed its total return for 2014 in excess of 27 percent.
A look at the chart below shows XLV recently attaining a new all-time high after briefly touching its 200-day average just six weeks ago.
From a comparative standpoint, the broad-based SPDR S&P 500 ETF Trust (NYSE: SPY) has gained 12.6 percent this year.
XLV, the largest and most well-known ETF in the health care sector, tracks 57 large-cap stocks engaged in pharmaceutical, biotechnology and medical services. Currently, this fund has more than $12.8 billion in total assets and charges an expense ratio of 0.16 percent.
The largest holdings include Johnson & Johnson, Pfizer Inc. and Merck & Co., Inc. Combined, these three mega-cap stocks represent more than 25 percent of the total XLV portfolio.
SPDR S&P Biotech
The health care sector has continued to flourish in the wake of continued innovation in medical devices, biotechnology and essential services. The biotechnology sector in particular has been characterized by marked enthusiasm behind several mergers and acquisitions in 2014. In addition, the recent fears over an Ebola outbreak have highlighted the need for further spending in the health care arena.
The SPDR S&P Biotech (ETF) (NYSE: XBI) tracks 84 stocks engaged in biotechnology research. This ETF has gained an impressive 38.9 percent this year as it continues to trade near all-time highs as well.
For now, the momentum appears to be working in favor of the health care sector and continued strength in the broad market may carry it even higher.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.